Deficiency in cellular thiol tripeptide glutathione (L-γ glutamyl-cysteinyl-glycine) determines the severity of several chronic and inflammatory human diseases that may be relieved by oral treatment with the glutathione precursor N-acetylcysteine (NAC).
Neutral sphingomyelinase inhibition participates to the benefits of Nacetylcysteine treatment in post-myocardial infarction failing heart rats
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INTRODUCTION
Oxidative stress and the proinflammatory cytokine tumor necrosis factor-α (TNF-α) are involved in the pathogenesis of several inflammatory and degenerative disorders [1] [2] [3] [4] , and are, in particular, major interrelated contributors to chronic heart failure (CHF) progression [5] [6] [7] [8] [9] .
The tripeptide glutathione (L-γ glutamyl-cysteinyl-glycine) does not only play a key role in cell defence against oxidative stress, but also participates to many other metabolic cell functions [10] . We previously reported that glutathione status determines TNF-α adverse effects in heart [11, 12] . Herein we addressed the question as to whether glutathione deficiency might be causally linked to the exacerbated TNF-α activation occurring in well-established CHF, as this was observed in several other chronic diseases including HIV infection [13, 14] , neurodegeneration [1, 15] , muscular fatigue [14] , rheumatoid arthritis [3] and chronic lung diseases [16, 17] . Of note, the well-being of the patients affected with those diseases is improved by treatment with the glutathione precursor N-acetylcysteine (NAC) [13, 14, 18, 19] . Previous studies pointed out the decrease in cardiac GSH/ GSSG ratio in CHF [20, 21] . However, the possible deficiency in total glutathione in the failing heart, and its related possible metabolic consequences have been overlooked.
TNF-α is not expressed in the normal heart but is upregulated in the failing heart [7, 22, 23] . TNF-α exerts its main biological functions in its soluble form (sTNF-α), binding to the membrane TNF-R1 receptor that mediates multiple distinct pathways [24] , including oxidative stress and neutral sphingomyelinase (N-SMase) activation.
Noteworthy, both pathways are subdued by glutathione. In its both reduced (GSH) and oxidized (GSSG) forms, glutathione serves as a natural inhibitor of N-SMase [25] , which hydrolyzes sphingomyelin into ceramide, controlling the sphingolipid signaling cascade [26] [27] [28] and mediating TNF-α apoptotic [29] and negative inotropic effects in cardiomyocytes [11, 30, 31] . Downstream ceramide generation, the ordered cascade of events in N-SMase pathway comprises downregulation of the prosurvival factor Bcl-2, resulting into a decrease of the proapoptotic Bax/ prosurvival Bcl-2 protein ratio that in turn elicits activation of caspase-3 [32] .
We have chosen the model of post-myocardial infarction (MI) rat, displaying a cardiac disease relevant with that of elderly and/or established CHF patients [33] . We show that total cardiac left ventricle (LV) glutathione is depleted in CHF patients and CHF post-MI rats. Glutathione repletion, achieved by oral NAC treatment in post-MI HAL author manuscript inserm-00158065, version 1 HAL author manuscript inserm-00158065, version 1 HAL author manuscript inserm-00158065, version 1 rats, prompts cardiac function and tissue recovery. Inhibition of N-SMase/ Bcl-2/ caspase-3 pathway participates to the beneficial effects of NAC treatment.
MATERIALS AND METHODS

Patients
The usage of surgical heart samples unused for diagnostic purpose was in accordance with the legislation and good clinical practice in France. LV samples were collected from unused explanted hearts of patients undergoing transplantation for endstage heart failure secondary to idiopathic dilated cardiomyopathy (n=3) or ischemic heart disease (n=3) (6 male, mean age of 52 ± 4 years, mean LV ejection fraction of 18 ± 4 %). Non -failing donor hearts (4 male and 2 female; mean age of 30 ± 3 years), which were unsuitable for transplantation for technical reasons, were used as controls.
Myocardial tissue samples were obtained at the time of explant, immediately frozen in liquid nitrogen and stored at -80°C.
Animals and experimental design
Animal procedures were conducted in accordance with French government policies (Services Vétérinaires de la Santé et de la Production Animale, Ministère de l'Agriculture). The experimental design is described in Fig.1 .
Induction of myocardial infarction (MI) in rats.
We produced MI by ligation of the left coronary artery in 11 week-old male Wistar rats, anesthetized with Ketamine and Xylazine (60 and 5 mg/kg, respectively, intraperitoneally) [33] . MI resulted in a mean 41% infarct size ( Table 1) . Sham-operated rats were subjected to the same protocol, except that the snare was not tied. Animals were then euthanized, hearts were removed, rapidly frozen in isopentane cooled with liquid nitrogen, and stored at -80°C.
LV morpho-histological assessment
Heart sections were cut into 5 µm slices that were mounted onto slides (Superfrost Plus, Menzel-Glaser). Slices were stained with Sirius red F3BA (0.1% solution in saturated aqueous picric acid) to color collagen. Infarct size was calculated as (endocardial + epicardial circumference of the infarcted tissue)/(endocardial + epicardial circumference of the LV). as previously described [33] . Results obtained from 4 to 6 hearts were expressed as a percentage ± sem. Interstitial collagen density in the noninfarcted LV was quantified by examining 6-10 random high-power fields in each heart (magnification, x100 hearts were expressed as a percentage ± sem. Mean cardiomyocyte cross-sectional area in the noninfarcted LV was determined in hematoxylin-eosin-stained slices by examining 4 random high-power fields in each heart (magnification, x200). Images were analyzed using a NIH Image analysis system. Results were obtained from 4 hearts in each group.
LV homogenate preparation and biochemical assays
The noninfarcted part of the LV was cut into 20 µm sections. Homogenates were prepared from 5 frozen sections of each LV by homogenization at 4°C, in 200 µl of 50 mM Hepes, pH 7.4, containing protease inhibitors (1mM PMSF, 2 µg/ ml leupeptin, 2 µg/ ml aprotinin), using disposable pestle/ microtube devices (Fisher Scientific Labosi).
Glutathione was measured in LV homogenates according to a modification of Tietze as previously described [12] . N-SMase activity was determined in LV homogenates as previously described [11] .
sTNF-α and TNF-R1 were quantified in LV homogenate fractions, obtained after centrifugation at 4°C at 20,000xg for 20 min. The supernatant, containing sTNF-α, was stored at -80°C until use. The pellet, containing the membrane fraction, was resuspended by homogenization in the Hepes buffer containing protease inhibitors, and 1% Triton X-100. After 30 min incubation on ice, the suspension was centrifuged at 20,000 x g for 20 min to remove debris, and the supernatant, containing the solubilized membrane-bound TNF-R1, was stored at -80°C until use. sTNF-α and TNF-R1 were quantified with ELISA kits (Quantikine, R&D Systems).
Western blot analysis
For Western blot analysis, proteins of the LV homogenate (caspase-3) or the 20,000 x g pellet fraction (Bcl-2 and Bax proteins) were resolved with 12.5% SDSpolyacrylamide gels using a 4% stacking gel. Proteins were transferred to polyvinylidene difluoride (PVDF) membranes (0.22 µm, Millipore) by electroblotting. and quantified by scanning densitometry using a NIH Image anlysis system. Loading and protein transfers were verified with a mouse anti-ß-actin antibody (1:5,000, Sigma).
RNA preparation and RT-PCR
Total RNA were extracted from 5 pooled frozen LV sections, using Tri reagent (Sigma). Semi-quantitative RT-PCR was carried out on a Light Cycler (Roche Diagnostic), as previously described [35] . controlled on a 2% agarose gel and sequenced.
Statistical analysis
Results are given as means ± sem of determinations done in at least 5 different LV. Because measurements of echocardiographic, hemodynamics and biochemical parameters gave similar results for the 2-and 3-month sham subgroups, for simplification, data were pooled into one sham group. Data were analyzed by the Mann-Whitney test (GraphPad Software Inc). Differences were considered statistically significant at P < 0.05.
RESULTS
Deficiency in glutathione is a common feature of failing human LV and failing post-MI rat LV.
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We analyzed total glutathione content in LV samples of unused explanted hearts from normal individuals and from patients with end-stage dilated or ischemic cardiomyopathies. Total glutathione content was decreased by 54% in failing human LV compared with control (Fig. 2a) . Total glutathione was also decreased by 40% in the 2-and 3-month post-MI rats (Fig.2b) .
Next, we examined whether glutathione repletion achieved by oral treatment with NAC might improve heart recovery in post-MI rats.
In post-MI rats, 1-month NAC treatment replenished LV glutathione, improved LV function and reduced LV fibrosis.
Transthoracic echocardiography showed marked deterioration in LV contractile function of 2-month post-MI rats compared to sham rats, as expressed by reduced percent fractional shortening (FS; Table 1 ). Systolic and diastolic functions were also markedly lessened, as illustrated by marked decrease in cardiac output and LV dP/dtmax, and increase in Tau relaxation factor and LV dP/dtmin, respectively ( Table   1) . LV dysfunction did not significantly worsen in 3-month post-MI rats proving that 2-month post-MI rats displayed well-established CHF ( Table 1) .
One-month NAC treatment, given as food additive (120 mg.kg -1 .day -1 ) to CHF 2-month post-MI rats, normalized LV glutathione (Fig.2b) , and improved LV function in 3-month post-MI group compared to untreated 3-month post-MI rats, as demonstrated by significant recovery of FS, systolic and diastolic function ( Table 1) . NAC-treated 3-month post-MI rats also displayed a trend towards retrieval compared to 2-month post-MI rats that reached significance for cardiac output ( Table 1) . One-month NAC treatment had no effect on the systolic blood pressure of post-MI rats ( Table 1) . This finding is consistent with our previous report that NAC treatment improved the cardiac function in the L-NAME hypertensive rat model (rats treated with the nitric oxide synthase inhibitor, L-NAME), without lessening hypertension [12] . Nevertheless, the absence of change in blood pressure together with an increase in cardiac output, implies that NAC treatment decreases systemic vascular resistance.
LV dilatation and hypertrophy, as assessed by enlarged LV diameter ( Table 1) and increased heart weight (HW), normalized to body weight (BW), are two features of post-MI hearts (Fig.3a) . The increase in HW/ BW ratio in post-MI rats was consistent with the presence of enlarged cardiomyocytes (cross-sectional width 32.1±0.8µm to compare with sham: 23.5 ± 0.6 µm; P<0.05, Fig.3b ), next to interstitial collagen deposits in the noninfarcted LV. Fibrosis (Fig.3c ) and re-expression of fetal atrial natriuretic peptide (ANP) and myosin heavy chain (MHC)-ß isoform genes (Fig.3d) attested to pathological hypertrophy [36] [37] [38] [39] . One-month NAC treatment did not lessen hypertrophy (Fig.3a) . In fact, large cardiomyocytes were apparent in noninfarcted LV of NAC-treated 3-month post-MI rats, close to collagen fibres (cross-sectional width:
27.7 ± 0.6 µm; P<0.05 vs sham) (Fig.3b) . But, importantly, noninfarcted LV in NACtreated 3-month post-MI rats displayed reduced fibrosis (Fig.3c ) and decreased expression of ANP and MHC-ß genes expression (Fig.3d) , which was consistent with the observed recovery of LV function in NAC-treated post-MI rats.
Glutathione repletion is associated with early and persisting Inhibition
of N-SMase/ Bcl-2/ caspase-3 cascade, and with late reduction in sTNF-α expression and oxidative stress.
Next experiments aimed to get insight into the biochemical mechanisms underlying the functional and structural benefits of NAC treatment. The biochemical studies were performed at 3-day and 1-month time-points of NAC treatment given to 2 months post-MI rats. In fact, at the early 3-day time-point, NAC treatment had no effect on the cardiac phenotype of 2 months post-MI rats ( Table 1) , but partly replenished LV glutathione to 75% of its control level in sham rats (Fig.2b) . Thus, examination of the biochemical parameters after 3-day NAC treatment should allow identification of the early mechanisms preceding and likely to drive changes in the cardiac pathophysiological status. Because N-SMase is a direct target of glutathione, and a sensitive sensor to changes in cellular glutathione [40] , we focused on the N-SMase/ Bcl-2/ caspase-3 cascade. N-SMase was stimulated by about 2-fold in noninfarcted LV of post-MI rats, compared with sham LV (Fig.4a ). In accordance with the scheme of NSMase cascade pathway, and with previous observation that deficiency in glutathione leads to the degradation of Bcl-2 protein [41] , Bcl-2 protein was decreased in the noninfarcted LV of 2-and 3-month post-MI rats, without significant alteration of Bax protein (Fig.4b, typical) . The resulting 50-60% decrease in Bcl-2/Bax ratio (Fig.4b, densitometric evaluation) was associated with increased amount of cleaved caspase-3, 17/ 19 kDa fragments, illustrating caspase-3 activation (Fig.4c) . One major finding of this study is that 3-day NAC treatment blunted N-SMase activation, replenished Bcl-2 content and inhibited caspase-3 activation in noninfarcted LV of 2-month post-MI rats (Fig.4a-b-c) . Importantly, the reversal effect of NAC treatment on N-SMase activity, Bcl-2 expression and caspase-3 activity persisted after 1-month (Fig.4a-b-c) .
sTNF-α, which is a major contributor to CHF progression, triggers N-SMase HAL author manuscript inserm-00158065, version 1 HAL author manuscript inserm-00158065, version 1 HAL author manuscript inserm-00158065, version 1 activation through TNF-R1. As shown in Fig. 5a , and as previously reported [7] , sTNF-α was not detectable in LV of sham rat (<10 pg sTNF-α/mg prot), but was markedly expressed in noninfarcted LV of 2-and 3-month post-MI groups (Fig.5a ), whereas TNF-R1 protein expression was similar in sham and post-MI LV (Fig.5b) . After 3-day NAC treatment, expression of sTNF-α and TNF-R1 remained unchanged in noninfarcted LV of 2-month post-MI rats. In contrast, 1-month NAC treatment reduced the expression of both proteins by 46% and 51%, respectively, in noninfarcted LV of 3-month post-MI rats (Fig.5a-b) .
The decrease in oxidative stress injury brought by NAC treatment has been associated with regression of fibrosis in hypertensive rats with sub-acute LV remodelling [12] and in mice with hypertrophic cardiomyopathy [42] . In the noninfarcted LV of 2-and 3-month post-MI rats, H 2 O 2 release, assessed as an index of reactive oxygen species production, and lipid peroxidation by-products (LPO) accumulation were increased by 5-to 7-and 2-fold, respectively, compared with sham rats (Fig.6 a-b) . Three-day NAC treatment had no significant effect on the oxidative stress injury in noninfarcted LV of 2-month post-MI rats (Fig.6 a-b) . But, as expected, after 1-month NAC treatment, H 2 O 2 release and LPO resumed control values in LV of 3-month post-MI rats (Fig.6 a-b) .
Taken together, these results suggesed that cardiac tissue and function recovery, brought by NAC treatment to the failing post-MI heart, were associated with decreased expression of sTNF-α and TNF-R1, inhibition of N-SMase and caspase-3, increase in Bcl-2/ Bax ratio and blunting of oxidative stress, illustrating the disruption of the vicious sTNF-α/ TNF-R1 signalling cycle.
DISCUSSION
The new findings of this study are twofold. Firstly, the failing human heart displays a deficiency in total glutathione that is reproduced in a rat model of post-MI failing heart. Secondly, replenishment in cardiac glutathione, achieved in post-MI rats by oral NAC treatment, elicits recovery of cardiac tissue and function.
Previous studies have pointed out changes in the redox status of glutathione in the failing heart [20] , but have overlooked a possible deficiency in glutathione content.
Likewise, trials with antioxidants in patients with risks of cardiovascular diseases included antioxidants such as vitamin-E and vitamin-C gave disappointing results [43] , but ignored glutathione or glutathione precursors. Of note, antioxidants cannot indiscriminately be lumped together. Vitamin-E, vitamin-C and glutathione participate in an antioxidant network in which glutathione plays a pivotal role, recycling other antioxidants and keeping them in their active state. Vitamins will not compensate for severe deficiency in glutathione synthesis. Furthermore, antioxidants also differ from each other because of unrelated antioxidant properties such as N-SMase inhibition by glutathione [25] , sirtuin activation by resveratrol [44] , inhibition of PMP22 expression by vitamin-C [45] .
N-SMase activation is described as an early event in ischemia/ reperfusion injury [46, 47] , that is persisting in the chronic failing heart of 2-and 3-month post-MI rats.
Partial repletion in cardiac glutathione of 2-month post-MI rats after 3-day NAC treatment blunts N-SMase activation specifically, which is consistent with the previously reported N-SMase inhibitory effect of glutathione. In contrast, full repletion in cardiac glutathione of 3-month post-MI rats after 1-month NAC-treatment is not only associated with a persistent low N-SMase activity, but also with a decreased expression in sTNF-α/ TNF-R1. On its own, sTNF-α/ TNF-R1 triggers FAN-mediated N-SMase activation. Hence, one may expect that long-term normalization of N-SMase activity does not only rely on enzyme inhibition by glutathione, as after 3-day NACtreatment, but also on the collapse of its activation by sTNF-α. In any way, an overall outcome of glutathione repletion is the disruption of the TNF-α/ TNF-R1/ N-SMase signalling cycle. In fact, the effects of NAC treatment resemble those provided by TNF-α or TNF-R1 ablation, opposite to the deleterious effects brought by sTNF-α overexpression [48] . Thus, ablation of TNF-R1 or TNF-α in mice leads to a better post-MI preservation of the cardiac function compared with post-MI WT mice [49, 50] . Onemonth post-MI LV of TNF-α ablated mice also displayed lower collagen volume than post-MI WT mouse LV [50] . Finally, in mice with TNF-α-induced CHF, TNF-R1 ablation preserves cardiac function [51] .
Of note, caspase-3 activation in LV of 2-and 3-month post-MI rats was not associated with nuclear DNA fragmentation assessed by DAPI staining (not shown), a finding consistent with previous studies using different experimental models of heart failure, including that of post-ischemia/ reperfusion mouse overexpressing caspase-3 in the heart [52, 53] . In their study Condolleri et al. [52] showed that cardiac specific caspase-3 expression induced transient depression of cardiac function and abnormal nuclear and myofibrillar ultrastructural damage. And when subjected to myocardial ischemia-reperfusion, caspase-3 transgenic mice showed increased infarct size and a higher susceptibility to die. However, DNA laddering, used as the test for apoptosis, was similar in caspase-3 overexpressing mice and control mice, having undergone, or HAL author manuscript inserm-00158065, version 1 HAL author manuscript inserm-00158065, version 1 HAL author manuscript inserm-00158065, version 1 not, ischemia/ reperfusion. Thus, this study provided evidence that partial activation of caspase-3 was compatible with life. Likewise, in isolated adult rat cardiomyocytes, Communal et al [54] have observed that, in the early phase of apoptosis when no major DNA cleavage occurred, caspase-3 activation elicited the cleavage of myofibrillar proteins. Hence, under conditions where the apoptotic response is not completed, caspase-3 activation is likely to damage nuclear and myofibrillar proteins, which will prompt contractile dysfunction before cell death.
Other mechanisms are prone to participate to the beneficial effects of NAC treatment. Thus, glutathiolation of caspase-3, relying on cellular glutathione availability, hinders TNF-α-induced, caspase-8-mediated enzyme cleavage [55] . Differently, the antioxidant capacity of NAC is considered as its major attribute. Indeed, 1-month NAC treatment reduced oxidative stress in post-MI hearts. However, in contrast to N-SMase activation, oxidative stress did not significantly lessen within 3-day NAC treatment.
Hence, beneficial effects of NAC treatment to post-MI heart may rely on both nonantioxidant effects and the global antioxidant capacity of glutathione.
Finally, it should be noted that recovery of the contractile function promoted by NAC treatment is not only associated with the improvement of cardiac parameters, but also with a decrease in systemic vascular resistance. Because cardiac iNOS expression was increased in post-MI rats, and normalized after 1-month NAC treatment (not shown), the improvement of hemodynamic function in NAC-treated rats more likely relied on the blunting of oxidative stress, including the neutralization of reactive nitrogen species, rather than on a NO mediated vasodilatory effect [56, 57] .
In cardiology, treatments with NAC were limited to acute syndromes [58] . Our results disclose NAC as a possible complementary treatment to current medical therapies for CHF patients. 
